Posts by Mourabit Halima

Could the gut microbiome be the missing link in understanding eating disorders? A groundbreaking study led by Dr. Sabrina J.P. Huwart, Dr. Nuria Morales-Puerto, and Dr. Amandine Everard (Université catholique de Louvain) sheds light on the interplay between gut microbiota, neuroinflammation, and food reward alterations—a critical factor in the development of eating disorders like anorexia nervosa, bulimia nervosa, and binge eating disorder.

The CheckMate 8HW trial, presented at the ASCO Gastrointestinal Cancers Symposium by Thierry Andre, is a randomized, multicenter, open-label phase 3 study evaluating the efficacy and safety of nivolumab (NIVO)…

The 2025 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU 2025) has already taken place in San Francisco, USA. This globally renowned academic event brought together top oncology scholars to jointly explore the cutting-edge breakthroughs and future directions in the field of genitourinary oncology.In this insightful exchange, Dr. Xuefeng Qiu from the Nanjing Drum Tower Hospital and Dr. Darren Poon from the Hong Kong Sanatorium and Hospital Comprehensive Cancer Center,China discuss key advances in mCRPC treatment, focusing on PARP inhibitors, ARPIs, and radioligand therapy. While genomic testing is shaping precision medicine, uncertainties remain regarding the benefit of PARP-ARPI combinations in ARPI-refractory patients. Dr. Poon highlights the potential of lutetium-177 PSMA therapy, especially for patients without prior chemotherapy.As precision oncology evolves, balancing efficacy, toxicity, and quality of life remains crucial. We appreciate our experts' insights and look forward to continued progress in prostate cancer treatment.